TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. PLAQUE PSORIASIS MARKET,BY TREATMENT
6.1. Overview
6.2. Topical Therapy
6.3. Phototherapy
6.4. Systemic Agents
6.5. Biologic Therapies
6.6. Others
7. PLAQUE PSORIASIS MARKET,BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Oral
7.3. Injectable
8. PLAQUE PSORIASIS MARKET,BY END USERS
8.1. Overview
8.2. Hospitals
8.3. Homecare
8.4. Speciality Centres
8.5. Others
9. PLAQUE PSORIASIS MARKET, BY DISTRIBUTION CHANNEL
9.1. Overview
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. PLAQUE PSORIASIS MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Plaque psoriasis market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Plaque psoriasis market,
11.7. Key developments and Growth Strategies
11.7.1. New ProductLaunch/Service Deployment
11.7.2. Merger &Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income,2022
11.8.2. Major Players R&D Expenditure.2022
12. COMPANY PROFILES
12.1. Pfizer Inc. (US)
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. GlaxoSmithKline plc (UK)
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Novartis AG (Switzerland)
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Mylan N.V. (US)
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Teva Pharmaceutical Industries Ltd.(Israel)
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Sanofi (France)
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Boehringer Ingelheim International GmbH. (Germany)
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. AstraZeneca (UK)
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Johnson & Johnson Private Limited (US)
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Bayer AG (Germany)
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Merck & Co., Inc. (US)
12.11.1. Company Overview
12.11.2. Financial Overview
12.11.3. Products Offered
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. F. Hoffmann-La Roche Ltd. (Switzerland)
12.12.1. Company Overview
12.12.2. Financial Overview
12.12.3. Products Offered
12.12.4. Key Developments
12.12.5. SWOT Analysis
12.12.6. Key Strategies
12.13. Bristol-Myers Squibb Company (US)
12.13.1. Company Overview
12.13.2. Financial Overview
12.13.3. Products Offered
12.13.4. Key Developments
12.13.5. SWOT Analysis
12.13.6. Key Strategies
12.14. Cadila Pharmaceuticals (India)
12.14.1. Company Overview
12.14.2. Financial Overview
12.14.3. Products Offered
12.14.4. Key Developments
12.14.5. SWOT Analysis
12.14.6. Key Strategies
12.15. Eli Lilly and Company (US)
12.15.1. Company Overview
12.15.2. Financial Overview
12.15.3. Products Offered
12.15.4. Key Developments
12.15.5. SWOT Analysis
12.15.6. Key Strategies
12.16. LEO Pharma A/S (Denmark)
12.16.1. Company Overview
12.16.2. Financial Overview
12.16.3. Products Offered
12.16.4. Key Developments
12.16.5. SWOT Analysis
12.16.6. Key Strategies
12.17. Cipla Inc. (US)
12.17.1. Company Overview
12.17.2. Financial Overview
12.17.3. Products Offered
12.17.4. Key Developments
12.17.5. SWOT Analysis
12.17.6. Key Strategies
12.18. Aurobindo Pharma (India)
12.18.1. Company Overview
12.18.2. Financial Overview
12.18.3. Products Offered
12.18.4. Key Developments
12.18.5. SWOT Analysis
12.18.6. Key Strategies
12.19. Lupin (India)
12.19.1. Company Overview
12.19.2. Financial Overview
12.19.3. Products Offered
12.19.4. Key Developments
12.19.5. SWOT Analysis
12.19.6. Key Strategies
12.20. Sumitomo Corporation (Japan)
12.20.1. Company Overview
12.20.2. Financial Overview
12.20.3. Products Offered
12.20.4. Key Developments
12.20.5. SWOT Analysis
12.20.6. Key Strategies
13. APPENDIX
13.1.1.
14. APPENDIX
14.1. References
14.2. Related Reports
LIST OF TABLES
TABLE 1 PLAQUE PSORIASIS MARKET, SYNOPSIS, 2018-2032
TABLE 2 PLAQUE PSORIASIS MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)
TABLE 3 PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 4 PLAQUE PSORIASIS MARKET,BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 5 PLAQUE PSORIASIS MARKET,BY END USERS, 2018-2032 (USD BILLION)
TABLE 6 PLAQUE PSORIASIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: PLAQUE PSORIASIS MARKET,BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: PLAQUE PSORIASIS MARKET,BY END USERS, 2018-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 11 US: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 12 US: PLAQUE PSORIASIS MARKET,BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 13 US: PLAQUE PSORIASIS MARKET,BY END USERS, 2018-2032 (USD BILLION)
TABLE 14 US: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 15 CANADA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 16 CANADA: PLAQUE PSORIASIS MARKET,BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 17 CANADA: PLAQUE PSORIASIS MARKET,BY END USERS, 2018-2032 (USD BILLION)
TABLE 18 CANADA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 1 EUROPE: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 3 EUROPE: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 4 EUROPE: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 5 GERMANY: PLAQUE PSORIASIS MARKET,BY TREATMENT,2018-2032 (USD BILLION)
TABLE 6 GERMANY: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 7 GERMANY: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 8 GERMANY: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 9 FRANCE: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 10 FRANCE: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 11 FRANCE: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 12 FRANCE: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 13 ITALY: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 14 ITALY: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 15 ITALY: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 16 ITALY: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 17 SPAIN: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 18 SPAIN: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 19 SPAIN: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 20 SPAIN: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 21 UK: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 22 UK: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 23 UK: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 24 UK: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 25 REST OF EUROPE: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 26 REST OF EUROPE: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 27 REST OF EUROPE: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 28 REST OF EUROPE: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 29 ASIA-PACIFIC: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 30 ASIA-PACIFIC: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 31 ASIA-PACIFIC: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 32 ASIA-PACIFIC: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 33 JAPAN: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 34 JAPAN: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 35 JAPAN: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 36 JAPAN: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 37 CHINA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 38 CHINA: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 39 CHINA: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 40 CHINA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 41 INDIA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 42 INDIA: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 43 INDIA: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 44 INDIA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 45 AUSTRALIA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 46 AUSTRALIA: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 47 AUSTRALIA: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 48 AUSTRALIA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 49 SOUTH KOREA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 50 SOUTH KOREA: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 51 SOUTH KOREA: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 52 SOUTH KOREA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 53 REST OF ASIA-PACIFIC: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 54 REST OF ASIA-PACIFIC: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 55 REST OF ASIA-PACIFIC: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 56 REST OF ASIA-PACIFIC: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 57 REST OF THE WORLD: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 58 REST OF THE WORLD: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 59 REST OF THE WORLD: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 60 REST OF THE WORLD: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 61 MIDDLE EAST: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 62 MIDDLE EAST: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 63 MIDDLE EAST: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 64 MIDDLE EAST: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 65 AFRICA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 66 AFRICA: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 67 AFRICA: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 68 AFRICA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
TABLE 69 LATIN AMERICA: PLAQUE PSORIASIS MARKET,BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 70 LATIN AMERICA: PLAQUE PSORIASIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 71 LATIN AMERICA: PLAQUE PSORIASIS MARKET, BY END USERS, 2018-2032 (USD BILLION)
TABLE 72 LATIN AMERICA: PLAQUE PSORIASIS MARKET,BY DISTRIBUTION CHANNEL,2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE PLAQUE PSORIASIS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE PLAQUE PSORIASIS MARKET
FIGURE 4 PLAQUE PSORIASIS MARKET, SHARE (%), BY TREATMENT, 2022
FIGURE 5 PLAQUE PSORIASIS MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2022
FIGURE 6 PLAQUE PSORIASIS MARKET, SHARE (%), BY END USERS, 2022
FIGURE 7 PLAQUE PSORIASIS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL,2022
FIGURE 8 PLAQUE PSORIASIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 NORTH AMERICA: PLAQUE PSORIASIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 EUROPE: PLAQUE PSORIASIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 ASIA-PACIFIC: PLAQUE PSORIASIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 REST OF THE WORLD: PLAQUE PSORIASIS MARKET, SHARE (%), BY REGION, 2022
FIGURE 13 PLAQUE PSORIASIS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 14 PFIZER INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 PFIZER INC. (US): SWOT ANALYSIS
FIGURE 16 GLAXOSMITHKLINE PLC (UK):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 GLAXOSMITHKLINE PLC (UK):SWOT ANALYSIS
FIGURE 18 NOVARTIS AG (SWITZERLAND):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 NOVARTIS AG (SWITZERLAND):SWOT ANALYSIS
FIGURE 20 MYLAN N.V. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 MYLAN N.V. (US):SWOT ANALYSIS
FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LTD.(ISRAEL):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD.(ISRAEL):SWOT ANALYSIS
FIGURE 24 SANOFI (FRANCE):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 SANOFI (FRANCE):SWOT ANALYSIS
FIGURE 26 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. (GERMANY): SWOT ANALYSIS
FIGURE 28 ASTRAZENECA (UK): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 ASTRAZENECA (UK): SWOT ANALYSIS
FIGURE 30 JOHNSON & JOHNSON PRIVATE LIMITED (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 JOHNSON & JOHNSON PRIVATE LIMITED (US): SWOT ANALYSIS
FIGURE 32 BAYER AG (GERMANY):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 BAYER AG (GERMANY):SWOT ANALYSIS
FIGURE 34 MERCK & CO., INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 MERCK & CO., INC. (US): SWOT ANALYSIS
FIGURE 36 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND):SWOT ANALYSIS
FIGURE 38 BRISTOL-MYERS SQUIBB COMPANY (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 BRISTOL-MYERS SQUIBB COMPANY (US):SWOT ANALYSIS
FIGURE 40 CADILA PHARMACEUTICALS (INDIA): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 CADILA PHARMACEUTICALS (INDIA):SWOT ANALYSIS
FIGURE 42 ELI LILLY AND COMPANY (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 ELI LILLY AND COMPANY (US):SWOT ANALYSIS
FIGURE 44 LEO PHARMA A/S (DENMARK):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 45 LEO PHARMA A/S (DENMARK): SWOT ANALYSIS
FIGURE 46 CIPLA INC. (US):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 47 CIPLA INC. (US):SWOT ANALYSIS
FIGURE 48 AUROBINDO PHARMA (INDIA):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 49 AUROBINDO PHARMA (INDIA):SWOT ANALYSIS
FIGURE 50 LUPIN (INDIA): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 51 LUPIN (INDIA):SWOT ANALYSIS
FIGURE 52 SUMITOMO CORPORATION (JAPAN):FINANCIAL OVERVIEW SNAPSHOT
FIGURE 53 SUMITOMO CORPORATION (JAPAN):SWOT ANALYSIS
